Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal The Indonesian Biomedical Journal Molecular and Cellular Biomedical Sciences (MCBS)
Angliana Chouw, Angliana
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Is Stem Cell a Curer or an Obstruction? Darmayanti, Siska; Triana, Rina; Chouw, Angliana; Dewi, Nurrani Mustika
Molecular and Cellular Biomedical Sciences Vol 1, No 1 (2017)
Publisher : Cell and BioPharmaceutical Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21705/mcbs.v1i1.12

Abstract

Stem cell research and therapy are progressing these days dramatically. Stem cell therapy holds enormous treatment potential for many diseases which currently have no or limited therapeutic options. Unfortunately, this potential also comes with side-effects. In this review, the positive and negative effects of regulation of stem cells will be explained. Stem cells are undifferentiated cells which able to develop into many different cells of types in the body during early life and growth. There are five types of stem cells: embryonic stem cells, induced pluripotent stem cells, somatic stem cells, fetal stem cells and mesenchymal stem cells. Stem cell transplantation is one form of stem cell therapy, it comes with different techniques sourced, and those are autologous and allogeneic transplantation stem cells. In an autologous transplant, a patients blood-forming stem cells are collected, meanwhile, in an allogeneic transplant, target cells are replaced with new stem cells obtained from a donor or donated umbilical cord blood. Its abilities to maintain the phenotype, self-renewing and differentiate itself into specialized cells, give rise to stem cell as an innovation for the treatment of various diseases. In the clinical setting, stem cells are being explored for different conditions, such as in tissue repair and regeneration and autoimmune diseases therapy. But along with its benefit, stem cell therapy also holds some harm. It is known that the treatment using stem cell for curing and rehabilitation has the risk of tumor formation.Keywords: stem cell, therapy, transplantation, tumorigenic, mesenchymal stem cell, allogeneic
Potency of Peripheral Blood- and Umbilical Cord Blood-derived Dendritic Cells and Their Secretomes as Vaccines for Cancer Haifa, Rima; Sartika, Cynthia Retna; Faried, Ahmad; Hadisaputri, Yuni Elsa; Chouw, Angliana; Wijaya, Andi; Barliana, Melisa Intan
Molecular and Cellular Biomedical Sciences Vol 8, No 1 (2024)
Publisher : Cell and BioPharmaceutical Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21705/mcbs.v8i1.358

Abstract

Dendritic cell (DC) vaccines, as immunotherapy agents, can gather up and transport cancer-related antigens to T lymphocytes, activating anti-tumor effector responses. After being activated by DC, cytotoxic T lymphocyte cells (CTL) will secrete the cytolytic granzyme B that can effectively induce rapid apoptosis of target cells. On the other hand, DC also secrete several cytokines and a large number of exosomes, which together operate as a whole antigen-presenting entity. The efficacy of the vaccine’s treatment may be affected by the sources used for DC vaccines. Umbilical cord blood (UCB) from healthy donors can be employed when autologous cancer patient’s peripheral blood (PB) cannot be used as a source for isolating DC due to genetic abnormalities. Comparing UCB to other sources, there is a painless method of collecting sources as opposed to PB, which necessitates a venipuncture or leukapheresis procedure to isolate the blood. Many studies related to the use of PB-DC have been carried out, but research on potential comparisons between PB-DC and UCB-DC is still very limited. In this review, the potential of PB- and UCB-derived DC and their secretomes for cancer will be discussed.Keywords: dendritic cells, vaccines, umbilical cord blood, peripheral blood
The Impact of Organoid to Assembloid Technology in Biomedical Research Meiliana, Anna; Chouw, Angliana; Askandar, Retina Shyallala; Woran, Blessari Tesalonika; Latarissa, Irma Rahayu; Wijaya, Andi
The Indonesian Biomedical Journal Vol 18, No 2 (2026)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v18i2.4052

Abstract

Organoids, three-dimensional, self-organized structures derived from pluripotent or adult stem cells, have revolutionized biomedical research by overcoming the inherent limitations of traditional 2D cultures and animal models. This review traces the evolution of organoid technology from initial studies to the contemporary "assembloid" phase, examining systemic inter-organ communication. The primary discovery of this review resides in the shift from descriptive modelling to a functional "Comparative Paradigm." A major perspective addressed is the transition from exclusively descriptive modelling to a functional 'Comparative Paradigm.' By merging developmental biology with bioengineering, a systematic framework is created to discover the most clinically relevant models, employing patient-derived 'avatars' to enhance personalized medicine and and high-throughput drug discovery. Ultimately, this review provides a systematic framework for identifying the most clinically applicable models by integrating developmental biology and bioengineering. The lack of vascularization, embryonic immaturity, and batch-to-batch repeatability issues remain major technical obstacles despite their potential. Finally, we explore potential future approaches in bioengineering, including the incorporation of 3D bioprinting, AI-driven imaging, and microfluidics (organ-on-a-chip). Organoid technology is a key component of next-generation medicine because it bridges the gap between "bench and bedside," providing previously unattainable insights into human biology and illness.KEYWORDS: organoids, stem cells, disease modeling, bioengineering, personalized medicine, assembloids, regenerative medicine; organ-on-a-chip, translational manufacturing
Co-Authors Ahmad Faried ANDI WIJAYA Anna Meiliana Askandar, Retina Shyallala Cynthia Retna Sartika, Cynthia Retna Haifa, Rima IRMA RAHAYU LATARISSA, IRMA RAHAYU Melisa Intan Barliana Nurrani Mustika Dewi, Nurrani Mustika Rina Triana, Rina Siska Darmayanti, Siska Woran, Blessari Tesalonika Yuni Elsa Hadisaputri